8-K: Xenetic Biosciences Reports Q3 2025 Results, Boosts Cash

Xenetic Biosciences, Inc. announced its third-quarter 2025 financial results, highlighting increased revenue and a recent capital raise to fund its immuno-oncology programs.

Summary

• Net loss for the quarter ended September 30, 2025, was approximately $0.5 million.
• Research & development expenses for the three months ended September 30, 2025, increased by approximately $0.4 million, or 105.6%, to approximately $0.8 million from $0.4 million in the comparable quarter in 2024.
• General and administrative expenses for the three months ended September 30, 2025, increased by approximately $0.1 million, or 9.3%, to approximately $0.8 million from approximately $0.7 million in the comparable quarter in 2024.
• Revenue for the three months ended September 30, 2025, increased by approximately $0.4 million, or 67.2%, to approximately $1.0 million from approximately $0.6 million for the three months ended September 30, 2024, primarily due to increased royalty revenue from a sublicense agreement with Takeda Pharmaceuticals Co. Ltd.
• The company ended the quarter with approximately $4.1 million in cash.
• Subsequent to quarter end, the company closed an underwritten offering for net proceeds of approximately $3.9 million.
• Xenetic continues to advance its systemic DNase I program towards Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors.
• Preclinical proof-of-concept studies combining DNase I with chemotherapy, immunotherapies, and CAR-T therapy in hematological and solid tumor and metastatic cancer models have been completed.

Sentiment

Score: 6

Explanation: The company reported increased revenue and successfully raised capital, which are positive. However, it also reported a net loss and significantly increased R&D and G&A expenses, indicating continued cash burn for development. The overall tone is cautiously optimistic about future clinical progress, but current financials show ongoing investment phase.

Positives

• Revenue increased by 67.2% to $1.0 million in Q3 2025, driven by higher royalty revenue from a sublicense agreement with Takeda Pharmaceuticals.
• Successfully completed an underwritten public offering in October 2025, securing approximately $3.9 million in net proceeds, which extends the cash runway.
• Continued execution on collaborations and exploratory investigator-initiated studies with institutional partners.
• Advanced the systemic DNase I program to mechanism-of-action and translational studies in preparation for a Phase 1 clinical trial.
• Completed preclinical proof-of-concept studies for DNase I in combination with chemotherapy, immunotherapies, and CAR-T therapy.

Negatives

• Net loss for Q3 2025 was approximately $0.5 million.
• Research & development expenses increased significantly by 105.6% to $0.8 million in Q3 2025, indicating increased burn rate.
• General and administrative expenses increased by 9.3% to $0.8 million in Q3 2025, partly due to increased legal costs in connection with a strategic review process.

Risks

• Unexpected costs, charges, or expenses resulting from manufacturing and collaboration agreements.
• Unexpected costs, charges, or expenses resulting from the licensing of the DNase platform.
• Uncertainty of the expected financial performance of the company following the licensing of the DNase platform.
• Failure to realize the anticipated potential of the DNase or PolyXen technologies.
• Inability to obtain funding and implement its business strategy.
• Risks and uncertainties regarding the outcome and timing of the strategic review process, including the possibility that the Board may decide not to undertake a strategic alternative, inability to consummate any proposed strategic alternative, disruption to business, and potential adverse effects on the company's stock price.
• Potential impacts of consummation of a strategic transaction on the company's current business operations, anticipated business strategy, and product development plans.
• Adverse effects from general market factors, economic and business conditions, public health issues, and geopolitical events (e.g., conflicts in Ukraine and the Middle East).
• Competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues, patent positions, litigation, and shareholder activism.

Future Outlook

Xenetic Biosciences intends to continue investing in preclinical efforts and exploratory studies to advance its DNase-based technology towards an Investigational New Drug (IND) submission and Phase 1 clinical trial initiation for pancreatic carcinoma and other locally advanced or metastatic solid tumors. The company expects its partnerships to generate critical data to guide development and regulatory strategies.

Management Comments

• "We are steadily building the foundation for potentially transformative progress in the oncology treatment paradigm as we advance our systemic DNase I program in combination with established cancer therapies."
• "The partnerships we've formed continue to generate critical data that we believe will help us guide our development and regulatory strategies to fully realize the promise of our DNase technology."
• "The underwritten public offering we completed in October 2025 extends our cash runway and provides us additional capital to continue to invest in pre-clinical efforts and exploratory studies and advance our technology toward an IND submission and Phase 1 initiation."

Industry Context

Xenetic Biosciences operates in the highly competitive immuno-oncology space, focusing on difficult-to-treat cancers. Its DNase platform aims to improve existing treatments by targeting neutrophil extracellular traps (NETs), a mechanism that could potentially enhance the efficacy of chemotherapies, immunotherapies, and CAR-T therapies. This approach aligns with the broader industry trend of developing adjunctive therapies to overcome resistance and improve patient outcomes in oncology.

Stakeholder Impact

• Shareholders: Potential for dilution from the recent capital raise, but also extended cash runway and continued investment in pipeline development could lead to future value creation if clinical trials are successful.
• Employees: Continued employment and focus on R&D.
• Customers (future patients): Potential for new treatment options for difficult-to-treat cancers if the DNase platform proves effective.
• Creditors: Improved liquidity due to the capital raise.

Next Steps

• Continue to invest in preclinical efforts and exploratory studies.
• Advance DNase-based technology toward an Investigational New Drug (IND) submission.
• Initiate Phase 1 clinical trials for pancreatic carcinoma and other locally advanced or metastatic solid tumors.
• Conduct mechanism-of-action and translational studies in preparation for Phase 1 clinical trials.
• PeriNess to lead regulatory approval, operational execution, and management of potential exploratory, investigator-initiated studies of recombinant DNase in Israeli medical centers.

Key Dates

Recommendation

While the company successfully raised capital and reported increased revenue, it continues to operate at a net loss with significant increases in R&D and G&A expenses, typical for a pre-clinical/early-clinical stage biopharmaceutical company. The progress in the DNase program towards Phase 1 is positive, but the inherent risks of drug development, particularly in oncology, remain high. The recent capital raise provides a longer runway, but further dilution or financing will likely be needed for later-stage trials. Investors should hold, awaiting more definitive clinical data and clearer milestones for the DNase platform.

Keywords

Xenetic Biosciences, XBIO, immuno-oncology, DNase I, pancreatic carcinoma, solid tumors, cancer therapy, clinical trials, biopharmaceutical, NETs, neutrophil extracellular traps, Q3 2025 earnings, capital raise, Takeda Pharmaceuticals